MA30086B1 - Derives de 3-alkylazetidine a substituants heterocycliques. - Google Patents
Derives de 3-alkylazetidine a substituants heterocycliques.Info
- Publication number
- MA30086B1 MA30086B1 MA31075A MA31075A MA30086B1 MA 30086 B1 MA30086 B1 MA 30086B1 MA 31075 A MA31075 A MA 31075A MA 31075 A MA31075 A MA 31075A MA 30086 B1 MA30086 B1 MA 30086B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- disorders
- useful
- compounds
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les nouveaux composés de formule développée (I) sont des antagonistes et/ou agonistes inverses du récepteur des cannabinoïdes-1 (CB1) et sont utiles dans le traitement, la prévention et la suppression des maladies régulées par le récepteur CB1. Les composés de la présente invention sont utiles comme médicaments actifs agissant de manière centrale dans le traitement des psychose, insuffisances de mémoire, troubles cognitifs, maladie d'Alzheimer, migraine, neuropathie, troubles neuro-inflammatoires y compris sclérose en plaques et syndrome de Guillain-Barre et les séquelles inflammatoires de l'encéphalite virale, accidents cérébraux vasculaires, et traumatisme crânien, troubles de l'anxiété, stress, épilepsie, maladie de Parkinson, troubles du mouvement, et schizophrénie. Les composés sont aussi utiles pour le traitement des troubles d'abus de substances, le traitement de l'obésité ou des troubles de l'alimentation, ainsi que le traitement de l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose du foie.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30086B1 true MA30086B1 (fr) | 2008-12-01 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31075A MA30086B1 (fr) | 2005-11-28 | 2008-06-25 | Derives de 3-alkylazetidine a substituants heterocycliques. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (fr) |
| KR (1) | KR20080073721A (fr) |
| AR (1) | AR058199A1 (fr) |
| BR (1) | BRPI0619018A2 (fr) |
| CR (1) | CR10014A (fr) |
| DO (1) | DOP2006000261A (fr) |
| EC (1) | ECSP088477A (fr) |
| IL (1) | IL191586A0 (fr) |
| MA (1) | MA30086B1 (fr) |
| NO (1) | NO20082919L (fr) |
| PE (1) | PE20070647A1 (fr) |
| RU (1) | RU2008126248A (fr) |
| SV (1) | SV2009002917A (fr) |
| TW (1) | TW200804317A (fr) |
| WO (1) | WO2007062193A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| AU2008317482A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of CB-1 antagonist/inverse agonist |
| WO2012031220A2 (fr) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Composés de nicotine et leurs analogues, procédés de synthèse pour fabriquer les composés et procédés d'utilisation |
| WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
| WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| CN1802351A (zh) * | 2003-06-11 | 2006-07-12 | 麦克公司 | 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物 |
| AU2006242219A1 (en) * | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/es unknown
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/ko not_active Withdrawn
- 2006-11-22 TW TW095143274A patent/TW200804317A/zh unknown
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/pt not_active IP Right Cessation
- 2006-11-22 EP EP06838347A patent/EP1954692A1/fr not_active Withdrawn
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/fr not_active Ceased
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/ru not_active Application Discontinuation
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/es not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/es unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/es not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/es unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/es not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/fr unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20082919L (no) | 2008-08-27 |
| RU2008126248A (ru) | 2010-01-10 |
| IL191586A0 (en) | 2008-12-29 |
| AR058199A1 (es) | 2008-01-23 |
| PE20070647A1 (es) | 2007-08-11 |
| TW200804317A (en) | 2008-01-16 |
| CR10014A (es) | 2008-07-29 |
| KR20080073721A (ko) | 2008-08-11 |
| BRPI0619018A2 (pt) | 2016-11-29 |
| EP1954692A1 (fr) | 2008-08-13 |
| ECSP088477A (es) | 2008-06-30 |
| SV2009002917A (es) | 2009-02-19 |
| DOP2006000261A (es) | 2007-07-15 |
| WO2007062193A1 (fr) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27847A1 (fr) | Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. | |
| MA30086B1 (fr) | Derives de 3-alkylazetidine a substituants heterocycliques. | |
| DE60334787D1 (de) | Substituierte amide | |
| MY134457A (en) | Substituted amides | |
| DE60316829D1 (de) | Substituierte furoä2,3-büpyridin derivate | |
| EP1492784A4 (fr) | 2,3-diphenyl-pyridines substituees | |
| WO2003086288A3 (fr) | Amides bicycliques | |
| WO2004058145A3 (fr) | Amides substitues | |
| WO2004029204A3 (fr) | Pyrimidines substituees | |
| DE602004024814D1 (de) | Substituierte naphthyridinonderivate | |
| WO2003082190A3 (fr) | Amides spirocycliques en tant que modulateurs du recepteur cannabinoide | |
| WO2003063781A3 (fr) | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide | |
| WO2003007887A3 (fr) | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides | |
| WO2008024284A3 (fr) | Pipérazines sulfonylées en tant que modulateurs du récepteur de cannabinoïde-1 | |
| ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
| NO20063381L (no) | CB1 modulatorforbindelser | |
| WO2007136607A3 (fr) | Esters substitués en tant que modulateurs récepteurs de cannabinoïde-1 | |
| US20190389865A1 (en) | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| DE602004024188D1 (de) | Des opioid-rezeptors | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| CA2522323A1 (fr) | Derives de 3-azabicyclo[3.2.1]octane comme ligands de recepteurs opioides | |
| WO2007064566A3 (fr) | Derives d'azetidine 3-alkyl substitues par heterocycle | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| WO2006041797A3 (fr) | Hydrazides acycliques utiles en tant que modulateurs du recepteur cannabinoide | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel |